Viatris Debt to Equity Ratio 2012-2026 | VTRS
Current and historical debt to equity ratio values for Viatris (VTRS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Viatris debt/equity for the three months ending June 30, 2026 was 0.81.
| Viatris Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2026-06-30 | $20.78B | $14.26B | 1.46 |
| 2026-03-31 | $22.18B | $14.66B | 1.51 |
| 2025-12-31 | $22.48B | $14.71B | 1.53 |
| 2025-09-30 | $22.70B | $15.22B | 1.49 |
| 2025-06-30 | $22.84B | $15.57B | 1.47 |
| 2025-03-31 | $22.83B | $15.65B | 1.46 |
| 2024-12-31 | $22.87B | $18.64B | 1.23 |
| 2024-09-30 | $24.96B | $19.79B | 1.26 |
| 2024-06-30 | $25.81B | $19.52B | 1.32 |
| 2024-03-31 | $27.33B | $20.01B | 1.37 |
| 2023-12-31 | $27.22B | $20.47B | 1.33 |
| 2023-09-30 | $27.88B | $20.87B | 1.34 |
| 2023-06-30 | $27.85B | $20.84B | 1.34 |
| 2023-03-31 | $28.36B | $20.93B | 1.36 |
| 2022-12-31 | $28.95B | $21.07B | 1.37 |
| 2022-09-30 | $29.48B | $19.18B | 1.54 |
| 2022-06-30 | $31.32B | $19.81B | 1.58 |
| 2022-03-31 | $33.02B | $20.45B | 1.62 |
| 2021-12-31 | $34.35B | $20.49B | 1.68 |
| 2021-09-30 | $34.93B | $21.14B | 1.65 |
| 2021-06-30 | $36.78B | $21.21B | 1.73 |
| 2021-03-31 | $37.57B | $21.42B | 1.75 |
| 2020-12-31 | $38.60B | $22.95B | 1.68 |
| 2020-09-30 | $18.70B | $12.55B | 1.49 |
| 2020-06-30 | $18.41B | $11.75B | 1.57 |
| 2020-03-31 | $18.88B | $11.26B | 1.68 |
| 2019-12-31 | $19.37B | $11.88B | 1.63 |
| 2019-09-30 | $19.59B | $11.46B | 1.71 |
| 2019-06-30 | $19.91B | $11.90B | 1.67 |
| 2019-03-31 | $20.02B | $11.89B | 1.68 |
| 2018-12-31 | $20.57B | $12.17B | 1.69 |
| 2018-09-30 | $21.39B | $12.07B | 1.77 |
| 2018-06-30 | $21.06B | $12.21B | 1.73 |
| 2018-03-31 | $22.01B | $13.18B | 1.67 |
| 2017-12-31 | $22.50B | $13.31B | 1.69 |
| 2017-09-30 | $22.53B | $13.29B | 1.70 |
| 2017-06-30 | $22.67B | $12.83B | 1.77 |
| 2017-03-31 | $22.62B | $11.66B | 1.94 |
| 2016-12-31 | $23.61B | $11.12B | 2.12 |
| 2016-09-30 | $24.71B | $11.83B | 2.09 |
| 2016-06-30 | $18.51B | $10.33B | 1.79 |
| 2016-03-31 | $12.37B | $10.28B | 1.20 |
| 2015-12-31 | $12.50B | $9.77B | 1.28 |
| 2015-09-30 | $11.50B | $9.82B | 1.17 |
| 2015-06-30 | $13.23B | $9.57B | 1.38 |
| 2015-03-31 | $13.03B | $9.09B | 1.43 |
| 2014-12-31 | $12.55B | $3.28B | 3.83 |
| 2014-09-30 | $11.77B | $3.41B | 3.46 |
| 2014-06-30 | $12.25B | $3.35B | 3.65 |
| 2014-03-31 | $12.16B | $3.19B | 3.81 |
| 2013-12-31 | $12.34B | $2.96B | 4.17 |
| 2013-09-30 | $9.67B | $3.23B | 2.99 |
| 2013-06-30 | $9.27B | $2.95B | 3.15 |
| 2013-03-31 | $9.00B | $2.89B | 3.12 |
| 2012-12-31 | $8.58B | $3.36B | 2.56 |
| 2012-09-30 | $8.08B | $3.62B | 2.23 |
| 2012-06-30 | $8.40B | $3.20B | 2.63 |
| 2012-03-31 | $8.16B | $3.78B | 2.16 |
| 2011-12-31 | $8.09B | $3.51B | 2.31 |
| 2011-09-30 | $7.62B | $3.49B | 2.18 |
| 2011-06-30 | $8.13B | $3.88B | 2.09 |
| 2011-03-31 | $7.96B | $3.92B | 2.03 |
| 2010-12-31 | $7.92B | $3.62B | 2.19 |
| 2010-09-30 | $7.86B | $3.54B | 2.22 |
| 2010-06-30 | $7.62B | $2.98B | 2.56 |
| 2010-03-31 | $7.64B | $3.18B | 2.41 |
| 2009-12-31 | $7.66B | $3.15B | 2.43 |
| 2009-09-30 | $7.69B | $3.07B | 2.50 |
| 2009-06-30 | $7.33B | $2.91B | 2.52 |
| 2009-03-31 | $7.25B | $2.65B | 2.74 |
| 2008-12-31 | $7.62B | $2.79B | 2.74 |
| 2008-09-30 | $8.05B | $2.98B | 2.70 |
| 2008-06-30 | $8.37B | $3.13B | 2.68 |
| 2008-03-31 | $8.44B | $3.16B | 2.68 |
| 2007-12-31 | $7.95B | $3.40B | 2.34 |
| 2007-09-30 | $2.59B | $1.89B | 1.37 |
| 2007-06-30 | $2.75B | $1.73B | 1.60 |
| 2007-03-31 | $2.61B | $1.65B | 1.58 |
| 2006-12-31 | $1.11B | $1.10B | 1.00 |
| 2006-09-30 | $1.08B | $0.96B | 1.13 |
| 2006-06-30 | $1.11B | $0.87B | 1.28 |
| 2006-03-31 | $1.08B | $0.79B | 1.38 |
| 2005-12-31 | $1.08B | $0.76B | 1.42 |
| 2005-09-30 | $1.08B | $0.83B | 1.30 |
| 2005-06-30 | $0.31B | $1.88B | 0.16 |
| 2005-03-31 | $0.29B | $1.85B | 0.16 |
| 2004-12-31 | $0.21B | $1.82B | 0.12 |
| 2004-09-30 | $0.21B | $1.78B | 0.12 |
| 2004-06-30 | $0.28B | $1.74B | 0.16 |
| 2004-03-31 | $0.22B | $1.66B | 0.13 |
| 2003-12-31 | $0.29B | $1.59B | 0.18 |
| 2003-09-30 | $0.27B | $1.53B | 0.17 |
| 2003-06-30 | $0.23B | $1.47B | 0.16 |
| 2003-03-31 | $0.30B | $1.45B | 0.21 |
| 2002-12-31 | $0.30B | $1.45B | 0.21 |
| 2002-09-30 | $0.24B | $1.47B | 0.16 |
| 2002-06-30 | $0.21B | $1.43B | 0.15 |
| 2002-03-31 | $0.22B | $1.40B | 0.16 |
| 2001-12-31 | $0.41B | $1.33B | 0.31 |
| 2001-09-30 | $0.40B | $1.25B | 0.32 |
| 2001-06-30 | $0.35B | $1.18B | 0.30 |
| 2001-03-31 | $0.33B | $1.13B | 0.29 |
| 2000-12-31 | $0.30B | $1.10B | 0.28 |
| 2000-09-30 | $0.27B | $1.06B | 0.26 |
| 2000-06-30 | $0.33B | $1.03B | 0.32 |
| 2000-03-31 | $0.14B | $1.20B | 0.11 |
| 1999-12-31 | $0.15B | $1.16B | 0.13 |
| 1999-09-30 | $0.14B | $1.12B | 0.12 |
| 1999-06-30 | $0.15B | $1.09B | 0.14 |
| 1999-03-31 | $0.15B | $1.06B | 0.14 |
| 1998-12-31 | $0.13B | $1.02B | 0.13 |
| 1998-09-30 | $0.12B | $0.81B | 0.15 |
| 1998-06-30 | $0.12B | $0.78B | 0.15 |
| 1998-03-31 | $0.10B | $0.74B | 0.14 |
| 1997-12-31 | $0.10B | $0.72B | 0.14 |
| 1997-09-30 | $0.12B | $0.70B | 0.17 |
| 1997-06-30 | $0.12B | $0.67B | 0.17 |
| 1997-03-31 | $0.12B | $0.66B | 0.18 |
| 1996-12-31 | $0.13B | $0.65B | 0.20 |
| 1996-09-30 | $0.13B | $0.64B | 0.20 |
| 1996-06-30 | $0.09B | $0.63B | 0.14 |
| 1996-03-31 | $0.08B | $0.62B | 0.12 |
| 1995-12-31 | $0.06B | $0.56B | 0.10 |
| 1995-09-30 | $0.05B | $0.54B | 0.09 |
| 1995-06-30 | $0.06B | $0.51B | 0.12 |
| 1995-03-31 | $0.06B | $0.48B | 0.13 |
| 1994-12-31 | $0.06B | $0.45B | 0.13 |
| 1994-09-30 | $0.05B | $0.43B | 0.11 |
| 1994-06-30 | $0.04B | $0.40B | 0.11 |
| 1994-03-31 | $0.02B | $0.38B | 0.06 |
| 1993-12-31 | $0.03B | $0.37B | 0.08 |
| 1993-09-30 | $0.03B | $0.35B | 0.08 |
| 1993-06-30 | $0.04B | $0.33B | 0.11 |
| 1993-03-31 | $0.06B | $0.30B | 0.19 |
| 1992-12-31 | $0.03B | $0.26B | 0.11 |
| 1992-09-30 | $0.03B | $0.23B | 0.13 |
| 1992-06-30 | $0.03B | $0.21B | 0.12 |
| 1992-03-31 | $0.02B | $0.20B | 0.11 |
| 1991-12-31 | $0.02B | $0.19B | 0.12 |
| 1991-09-30 | $0.02B | $0.17B | 0.12 |
| 1991-06-30 | $0.02B | $0.16B | 0.11 |
| 1991-03-31 | $0.02B | $0.17B | 0.12 |
| 1990-12-31 | $0.02B | $0.15B | 0.12 |
| 1990-09-30 | $0.02B | $0.14B | 0.13 |
| 1990-06-30 | $0.02B | $0.13B | 0.12 |
| 1990-03-31 | $0.01B | $0.13B | 0.08 |
| 1989-12-31 | $0.02B | $0.12B | 0.16 |
| 1989-09-30 | $0.01B | $0.11B | 0.11 |
| 1989-06-30 | $0.01B | $0.11B | 0.12 |
| 1989-03-31 | $0.01B | $0.10B | 0.08 |
| 1988-12-31 | $0.01B | $0.10B | 0.13 |
| 1988-09-30 | $0.01B | $0.10B | 0.12 |
| 1988-06-30 | $0.02B | $0.09B | 0.19 |
| 1988-03-31 | $0.02B | $0.09B | 0.21 |
| 1987-12-31 | $0.02B | $0.08B | 0.26 |
| 1987-09-30 | $0.02B | $0.08B | 0.25 |
| 1987-06-30 | $0.02B | $0.07B | 0.28 |
| 1987-03-31 | $0.01B | $0.07B | 0.18 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $19.136B | $14.300B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $142.882B | 25.03 |
| CVS Health (CVS) | United States | $122.206B | 12.19 |
| HCA Healthcare (HCA) | United States | $92.119B | 14.32 |
| Elevance Health (ELV) | United States | $92.005B | 14.44 |
| Cencora (COR) | United States | $62.254B | 19.02 |
| Natera (NTRA) | United States | $49.267B | 0.00 |
| Labcorp Holdings (LH) | United States | $25.572B | 18.03 |
| Medpace Holdings (MEDP) | United States | $16.619B | 34.90 |
| DiDi Global (DIDIY) | China | $16.275B | 178.51 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $16.114B | 0.00 |
| Solventum (SOLV) | United States | $15.290B | 12.65 |
| Revvity (RVTY) | United States | $14.338B | 24.02 |
| Charles River Laboratories (CRL) | United States | $13.038B | 27.59 |
| ICON (ICLR) | Ireland | $12.935B | 17.58 |
| BrightSpring Health Services (BTSG) | United States | $11.931B | 41.02 |
| Avantor (AVTR) | United States | $10.254B | 18.49 |
| BioMerieux (BMXMF) | France | $10.192B | 0.00 |
| HealthEquity (HQY) | United States | $7.944B | 25.89 |
| Caris Life Sciences,�Inc (CAI) | United States | $7.362B | 72.36 |
| PACS (PACS) | United States | $7.051B | 23.70 |
| Sonic Healthcare (SKHHY) | Australia | $6.687B | 0.00 |
| GETINGE (GNGBY) | Sweden | $6.654B | 18.79 |
| CochLear (CHEOY) | Australia | $6.355B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.282B | 23.76 |
| MiniMed (MMED) | United States | $6.181B | 0.00 |
| Sotera Health (SHC) | United States | $5.285B | 21.79 |
| Concentras Parent (CON) | United States | $4.566B | 22.52 |
| Organon (OGN) | United States | $3.585B | 4.55 |
| CareDx (CDNA) | United States | $2.709B | 308.06 |
| Alignment Healthcare (ALHC) | United States | $2.684B | 68.11 |
| GeneDx Holdings (WGS) | United States | $2.676B | 249.28 |
| Amplifon S.p.A (AMFPF) | Italy | $2.466B | 12.74 |
| Pediatrix Medical (MD) | United States | $2.187B | 12.81 |
| Establishment Labs Holdings (ESTA) | United States | $2.143B | 0.00 |
| Progyny (PGNY) | United States | $2.137B | 30.27 |
| COMPASS Pathways (CMPS) | United Kingdom | $2.013B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $1.914B | 0.00 |
| Surgery Partners (SGRY) | United States | $1.838B | 70.20 |
| Bora Pharmaceuticals, - (BORAY) | Taiwan | $1.695B | 10.18 |
| Freenome (FRNM) | United States | $1.607B | 0.00 |
| Ardent Health (ARDT) | United States | $1.552B | 8.87 |
| Agilon Health (AGL) | United States | $1.551B | 0.00 |
| Nutex Health (NUTX) | United States | $1.486B | 8.52 |
| InnovAge Holding (INNV) | United States | $1.470B | 0.00 |
| Omada Health (OMDA) | United States | $1.255B | 256.25 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.241B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.220B | 23.73 |
| Teladoc Health (TDOC) | United States | $1.181B | 0.00 |
| CryoPort (CYRX) | United States | $0.808B | 0.00 |
| GMR Solutions (GMRS) | United States | $0.716B | 0.00 |
| Enhabit (EHAB) | United States | $0.709B | 25.89 |
| Forward Industries (FWDI) | United States | $0.513B | 0.00 |
| Oncology Institute (TOI) | United States | $0.507B | 0.00 |
| Charming Medical (MCTA) | Hong Kong, SAR China | $0.504B | 0.00 |
| Strata Critical Medical (SRTA) | United States | $0.474B | 0.00 |
| SBC Medicals (SBC) | United States | $0.467B | 9.66 |
| Shoulder Innovations (SI) | United States | $0.382B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.377B | 5.47 |
| Embecta (EMBC) | United States | $0.297B | 2.57 |
| Biodesix (BDSX) | United States | $0.289B | 0.00 |
| So-Young (SY) | China | $0.266B | 0.00 |
| LifeMD (LFMD) | United States | $0.166B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.109B | 0.00 |
| Park Dental Partners (PARK) | United States | $0.101B | 0.00 |
| SkinHealth Systems (SKIN) | United States | $0.091B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.079B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.065B | 7.65 |
| Tevogen (TVGN) | United States | $0.049B | 0.00 |
| DocGo (DCGO) | United States | $0.037B | 0.00 |
| Lifeward (LFWD) | United States | $0.020B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.014B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.014B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.011B | 0.00 |
| Ainos (AIMD) | United States | $0.010B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.008B | 0.00 |
| Aclarion (ACON) | United States | $0.007B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.007B | 0.00 |
| 20/20 Biolabs (AIDX) | United States | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.006B | 0.00 |
| Pomdoctor - (POM) | China | $0.005B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.004B | 0.00 | |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Synergy CHC (SNYR) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |